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Methylome-wide Association Study 
of Atrial Fibrillation in Framingham 
Heart Study
Honghuang Lin1,2, Xiaoyan Yin1, Zhijun Xie2,3, Kathryn L. Lunetta1,4, Steven A. Lubitz5,6, 
Martin G. Larson1,7, Darae Ko9, Jared W. Magnani8, Michael M. Mendelson10,11, 
Chunyu Liu1,4,10, David D. McManus12, Daniel Levy1,10, Patrick T. Ellinor5,6 & 
Emelia J. Benjamin1,9,13,14
Atrial fibrillation (AF) is the most common cardiac arrhythmia, but little is known about the molecular 
mechanisms associated with AF arrhythmogenesis. DNA methylation is an important epigenetic 
mechanism that regulates gene expression and downstream biological processes. We hypothesize 
that DNA methylation might play an important role in the susceptibility to develop AF. A total of 
2,639 participants from the Offspring Cohort of Framingham Heart Study were enrolled in the current 
study. These participants included 183 participants with prevalent AF and 220 with incident AF 
during up to 9 years follow up. Genome-wide methylation was profiled using the Illumina Infinium 
HumanMethylation450 BeadChip on blood-derived DNA collected during the eighth examination 
cycle (2005–2008). Two CpG sites were significantly associated with prevalent AF, and five CpGs were 
associated with incident AF after correction for multiple testing (FDR < 0.05). Fourteen previously 
reported genome-wide significant AF-related SNP were each associated with at least one CpG site; 
the most significant association was rs6490029 at the CUX2 locus and cg10833066 (P = 9.5 × 10−279). 
In summary, we performed genome-wide methylation profiling in a community-based cohort and 
identified seven methylation signatures associated with AF. Our study suggests that DNA methylation 
might play an important role in AF arrhythmogenesis.
More than 30 million people worldwide are currently affected by atrial fibrillation (AF)1,2, the most common 
cardiac arrhythmia. AF is associated with a significantly increased risk for stroke3, dementia4, heart failure5–7, 
myocardial infarction8, and death9–11. In the past few years, genome-wide association studies (GWAS) have iden-
tified 14 genetic loci associated with AF12–15. However, none of these loci is located in protein coding regions, and 
the molecular mechanisms underlying the associations remain largely unknown.
DNA methylation refers to the process of adding a methyl group to the cytosine of cytosine-phosphate-guanine 
dinucleotides (CpG). DNA methylation stabilizes chromatin structure during transcription, which can regulate 
many downstream transcriptional processes. The methylation state can be transmitted through cell division, and 
can vary across multiple tissues16 or over an individual’s lifetime. Recent studies found that alteration of DNA 
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methylation is linked to many cardiovascular disease-related disorders, such as atherosclerosis17–20, high blood 
pressure21,22, and diabetes23–25. Several CVD risk factors, including smoking26, obesity27, and alcohol consumption28, 
are also associated with DNA methylation changes. However, there are no previous studies examining the relation 
of DNA methylation with prevalent or incident AF among community-based adults.
We hypothesized that DNA methylation might contribute to AF susceptibility. We performed a large-scale 
DNA methylation profiling study in participants from the Framingham Heart Study, and examined the associ-
ation of DNA methylation with prevalent and incident AF. Given the importance of DNA methylation to gene 
expression, we investigated the association of DNA methylation signatures of AF with gene expression from 
the same group of participants. We also assessed the association of GWAS loci for AF with DNA methylation to 
examine potential implications of AF-related genetic variants on DNA methylation.
Results
Differential Methylation. Table 1 shows the descriptive characteristics of 2,639 eligible participants (mean 
age 65 ± 9 years, 57% women), including 183 participants who developed AF before the eighth examination 
(prevalent AF), and an additional 220 participants who developed AF after the examination (incident AF) 
through follow-up in 2014.
Figure 1 shows the Manhattan plots of CpG sites associated with prevalent and incident AF. As shown in 
Table 2, two CpG were significantly associated with prevalent AF (FDR < 0.05). One significant CpG site was 
cg13639451 (P = 1.1 × 10−7, FDR = 0.03), located 1447 bp upstream of WFIKKN2, which encodes an endopep-
tidase inhibitor with a known role in muscle fiber development via inhibition of myostatin29. The other one 
was cg07191189 (P = 1.4 × 10−7, FDR = 0.03), located 75 bp upstream of STRN (Striatin). The CpG site also was 
predicted to affect the binding of transcription factor TFII-I30. Five CpG sites were associated with incident AF 
(FDR < 0.05). The most significant CpG site was cg26602477 (P = 4.7 × 10−9), located 207 bp downstream of 
SSU72. The results were similar when we additionally adjusted for different cell counts (Supplemental Table 1).
In our secondary analysis, we tested the associations of the seven significant prevalent or incident AF associ-
ated CpG sites adjusting for selected AF risk factors31, including smoking, height, weight, systolic blood pressure, 
diastolic blood pressure, prevalent diabetes mellitus, prevalent myocardial infarction, prevalent heart failure, and 
antihypertensive treatment. As shown in Supplemental Table 1, the results were similar to the primary analysis.
We also tested the association of methylation with all AF cases (combining prevalent and incident AF), but 
none of CpG site was significant after correction for multiple testing. The top CpG sites for all AF are listed in 
Supplemental Table 2.
We then examined if the inclusion of methylation profiles would improve the prediction of AF compared to 
traditional risk factors. Three models were tested: Model 1: Only included traditional risk factors associated with 
incident AF31; Model 2: Included traditional risk factors and 14 published AF-related genetic loci12–15; Model 
3: Included traditional risk factors, 14 known genetic loci associated with AF, and 5 CpG sites associated with 
incident AF. As shown in Fig. 2, the inclusion of genetic loci and methylation profiles modestly improved the 
prediction performance with area under curve (AUC) increasing from 0.729 (model 1) to 0.747 (model 2) and 
0.764 (model 3).
DNA Methylation Associated with Gene Expression. DNA methylation is an important mechanism 
to regulate gene expression. We tested if any of the seven AF-related CpG sites was associated with gene expres-
sion or not. We stratified our analysis by cis-gene associations (defined as those within 1 Mb of the CpG site), and 
trans-genes (defined as those more than 1 Mb away from the CpG site or in different chromosomes). A total of 
175 cis-associations and 124, 936 trans-associations were found and tested. Therefore the significance cutoff was 
0.05/175 = 2.9 × 10−4 for cis-associations and 0.05/124,936 = 4.0 × 10−7 for trans-associations. The most signifi-
cant cis- and trans- genes for each CpG site are shown in Table 3.
None of the cis-associations reached significance after adjusting for multiple testing (all with P > 2.9 × 10−4). 
Two AF-related CpG sites (cg13639451 and cg15440392) were associated with the expression trans-genes 
(P < 4.0 × 10−7). cg13639451 was associated with the expression of RPS18 (P = 4.5 × 10−20), and cg15440392 was 
associated with the expression of GZMH (P = 7.0 × 10−9).
Characteristics No AF (n = 2,236) Prevalent AF (n = 183) Incident AF (n = 220)
Women, n (%) 1285 (57%) 65 (36%) 89 (40%)
Age, year ± SD 65 ± 9 72 ± 9 71 ± 8
Height, inches ± SD 66 ± 4 67 ± 4 66 ± 4
Weight, pounds ± SD 173 ± 38 190 ± 48 181 ± 43
Current smoker, n (%) 206 (9%) 8 (4%) 15 (7%)
Systolic blood pressure, mm Hg 128 ± 17 128 ± 20 135 ± 19
Diastolic blood pressure, mm Hg 74 ± 10 70 ± 10 72 ± 10
Prevalent diabetes mellitus, n (%) 316 (14%) 60 (33%) 59 (27%)
Prevalent myocardial infarction, n (%) 18 (1%) 38 (21%) 8 (4%)
Prevalent heart failure, n (%) 68 (3%) 44 (24%) 14 (6%)
Antihypertensive treatment, n (%) 1016 (45%) 130 (71%) 142 (65%)
Table 1.  Clinical characteristics of studied samples.
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DNA Methylation Associated with AF-related Genetic Loci. DNA methylation may be regulated by 
both genetic and environmental factors. Fourteen AF-related SNPs have been previously reported12–15, however, 
their association with nearby DNA methylation has not been studied yet. For each AF-related SNP, we studied 
its association with the methylation of CpG sites within 1 Mb. A total of 6042 SNP-CpG pairs were identified 
and tested; therefore the significance cutoff was defined as P < 0.05/6042 = 8.3 × 10−6. As shown in Table 4, all 
the AF-related SNPs were significantly associated with methylation of at least one CpG site. The most significant 
association was between rs6490029 at the CUX2 locus and cg10833066 (P = 9.5 × 10−279). As shown in Fig. 3, the 
methylation level of cg10833066 increased with increasing copies of the “A” allele of rs6490029, which also was 
associated with higher AF risk according to previous GWAS13.
Discussion
DNA methylation is an important process regulating gene expression without changing DNA sequence. We per-
formed genome-wide methylation profiling of more than 2600 participants from the Framingham Heart Study 
Offspring cohort. Two CpG sites were found to be significantly associated with prevalent AF, and five other CpG 
sites were associated with incident AF. We also examined the association between methylation and GWAS loci 
for AF, and found that all AF loci were associated with the methylation of at least one CpG site, suggesting DNA 
methylation might be a possible mechanism through which AF-specific genetic variations affect gene regulation.
Interestingly, the most significant CpG site for prevalent AF (cg13639451) was also associated with the expres-
sion of the ribosomal protein RPS18 (P = 4.5 × 10−20). The gene has been shown to bind to CAMK2D32, a gene 
encoding a calcium/calmodulin-dependent protein kinase II that plays an important role in excitation-contraction 
coupling in the heart33. The other significant CpG site for prevalent AF, cg07191189, was located 75 bp upstream 
of STRN, which encodes striatin, a calmodulin-dependent scaffolding protein. Striatin has been shown to bind 
directly to caveolin-134, encoded by CAV1, which is involved in cardiac development35. Further, the CAV1 locus 
Figure 1. Manhattan plot of CpG sites associated with prevalent and incident AF. The x-axis represents the 
chromosome, and the y-axis represents the log10(p-value) of the associations with prevalent and incident AF. 
The horizontal line represents the significance cutoff (FDR = 0.05). We marked CpGs that were significantly 
associated with prevalent or incident AF (FDR < 0.05).
Type CpG site Chr Position+ Closest gene Distance Effect size SE* P value FDR*
Prevalent AF
cg13639451 17 48911157 WFIKKN2 1447 bp − 0.010 0.002 1.1 × 10−7 0.030
cg07191189 2 37193690 STRN 75 bp 0.011 0.002 1.4 × 10−7 0.030
Incident AF
cg26602477 1 1476845 SSU72 207 bp − 8.289 1.415 4.7 × 10−9 0.001
cg15440392 20 36156634 BLCAP 301 bp 4.808 0.823 5.1 × 10−9 0.001
cg04064828 10 134002751 DPYSL4 0 − 28.669 5.218 3.9 × 10−8 0.006
cg27529934 1 205054684 RBBP5 585 bp − 8.291 1.542 7.5 × 10−8 0.008
cg06725760 10 1102461 WDR37 314 bp 6.655 1.300 3.1 × 10−7 0.027
Table 2.  Most significant CpG sites associated with AF (FDR < 0.05). + NCBI Genome Build 37. *SE: 
Standard error; FDR: false discovery rate53.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:40377 | DOI: 10.1038/srep40377
was associated with AF in our previous GWAS12. Given that all known GWAS loci for AF are located in intergenic 
or intronic regions, our results suggest that methylation might act as an important bridge to link genetic variation 
and disease susceptibility.
The most significant CpG site for incident AF was cg26602477, located 207 bp away from SSU7, a gene encod-
ing a protein phosphatase that regulates the dephosphorylation process of RNA polymerase36. Another significant 
CpG site cg15440392 is located within BLCAP, which encodes a bladder cancer-associated protein. The gene is 
highly conserved through evolution and is expressed in a variety of human tissues including cardiac37. However, 
the implications of these genes for AF risk are still unknown.
The AF-related SNP rs6490029 was significantly associated with CpG site cg10833066, which is located 
~400 kb upstream of ALDH2, a gene encoding aldehyde dehydrogenase. Aldehyde dehydrogenase plays an 
important role in the metabolism of alcohol through catalyzing the oxidation of aldehydes into carboxylic acids. 
Previous studies have proven that excessive alcohol usage is associated with increased risk of AF38–40, suggesting 
that DNA methylation might be an important factor in AF susceptibility.
It is worth noting that there is no overlap between CpG sites that were associated with prevalent and incident 
AF. Several reasons might be responsible for the lack of overlap. Unlike genetic variations, the relations between 
DNA methylation and AF are reciprocal41, which means that not only DNA methylation could affect the suscep-
tibility of AF, the disease could also influence one’s methylation profile. Given that DNA methylation was profiled 
from whole blood collected during a routine examination, the methylation profile in samples with prevalent AF 
could have been influenced by AF for an extended period of time. In contrast, for samples with incident AF, the 
methylation profile could be one of factors that influenced their susceptibility to develop AF. In addition, there 
Figure 2. Receiver operating characteristic (ROC) curves of three models to predict incident AF. Model 1: 
Only included traditional risk factors; Model 2: Included traditional risk factors and 14 AF-related genetic loci; 
Model 3: Included traditional risk factors, 14 AF-related genetic loci, and 5 AF-related CpG sites. The inclusion 
of genetic loci and methylation profiles modestly improved the prediction performance with area under curve 
(AUC) increasing from 0.729 (model 1) to 0.747 (model 2) and 0.764 (model 3).
Type CpG site
Most significant cis-gene for each AF-related 
CpG site
Most significant trans-gene for each AF-related 
CpG site
Gene
Effect 
size SE P value Gene+
Effect 
size SE P value
Prevalent AF
cg13639451 HILS1 0.36 0.14 9.1 × 10−3 RPS18 1.85 0.20 4.5 × 10−20
cg07191189 STRN 0.35 0.12 4.8 × 10−3 LGSN 0.77 0.18 2.3 × 10−5
Incident AF
cg26602477 C1orf159 − 0.35 0.16 3.1 × 10−2 PTPN2 − 1.37 0.31 1.2 × 10−5
cg15440392 RPN2 0.21 0.12 7.8 × 10−2 GZMH − 2.18 0.37 7.0 × 10−9
cg04064828 DPYSL4 0.56 0.23 1.7 × 10−2 ABCA4 − 0.98 0.20 7.9 × 10−7
cg27529934 PLEKHA6 0.26 0.09 5.6 × 10−3 ADAMTS2 0.40 0.09 1.3 × 10−5
cg06725760 ZMYND11 − 0.22 0.21 2.8 × 10−1 GZMH − 3.01 0.72 3.2 × 10−5
Table 3.  Association of AF-specific CpG sites with the most significant cis-gene expression and trans-gene 
expression. *SE: Standard error. +All the most significant genes are located in different chromosomes from the 
corresponding CpG sites. *SE: Standard error.
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was a slight difference between the numbers of incident AF cases compared to prevalent AF cases, which might 
also have contributed to the variation in the methylation profile identified.
We acknowledge several limitations in our study. DNA methylation was collected at a single examination, 
so we were unable to investigate longitudinal changes in methylation profiles. Moreover, the DNA methylation 
profile was measured from whole blood, which could vary from levels in atria or specific white blood cell types. 
However, invasive specimen collection is not feasible in a community-based study. The participants in our study 
are largely middle-age to older and are of European decent, so it is unclear whether our findings are generalizable 
to other ages or races/ethnicities. As an observational study we cannot exclude residual confounding, or deter-
mine causal relationships. Given that many other cohorts have very limited numbers of AF cases with methyla-
tion profiling, and they are usually derived from different types of cells, we were unable to replicate our findings 
in the current study. Future studies with multiple examinations and population diversity might provide better 
understanding of methylation signatures for AF and are required to verify our findings.
In conclusion, we examined the association of DNA methylation with AF in a moderately large community- 
based cohort, and identified multiple methylation signatures associated with AF. Our results suggest that DNA 
methylation might represent an important bridge to link genetic variations with AF susceptibility. Future valida-
tion might uncover AF-specific methylation regulation mechanisms, and potentially lead to the identification of 
novel therapeutic targets for better treatment of AF.
AF SNP
Cloest gene 
to AF SNP CpG site Chr Position+
Closest gene 
to CpG site
Distance to 
AF SNP
Effect 
size SE* P value
Methylation 
to AF risk$
rs6490029 CUX2 cg10833066 12 111,807,467 FAM109A 109,010 bp 0.1380 0.0034 9.5 × 10−279 ↑ 
rs10824026 SYNPO2L cg02286717 10 75,415,704 SYNPO2L 5,504 bp − 0.0578 0.0018 1.3 × 10−190 ↑ 
rs1152591 SYNE2 cg23250157 14 64,679,961 SYNE2 887 bp − 0.0109 0.0005 2.8 × 10−97 ↓ 
rs7164883 HCN4 cg06757333 15 73,655,217 HCN4 3,043 bp − 0.0357 0.0019 1.3 × 10−71 ↓ 
rs3807989 CAV1 cg12739419 7 116,140,593 CAV2 45,648 bp 0.0233 0.0013 1.2 × 10−65 ↓ 
rs4642101 CAND2 cg24848339 3 12,840,334 CAND2 1,889 bp − 0.0112 0.0006 1.8 × 10−63 ↑ 
rs12415501 NEURL cg12662887 10 105,343,920 NEURL1 19,146 bp 0.0562 0.0034 7.5 × 10−59 ↑ 
rs6666258 KCNN3 cg06221963 1 154,839,813 KCNN3 25,545 bp 0.0714 0.0052 6.6 × 10−42 ↑ 
rs10507248 TBX5 cg10233830 12 114,701,413 TBX5 95,680 bp − 0.0311 0.0031 4.9 × 10−23 ↑ 
rs10821415 C9orf3 cg13792694 9 97,865,232 FANCC 151,773 bp − 0.0033 0.0004 7.1 × 10−20 ↓ 
rs3903239 PRRX1 cg09010107 1 170,638,807 PRRX1 69,490 bp 0.0116 0.0016 1.1 × 10−13 ↑ 
rs6817105 PITX2 cg03587884 4 111,642,146 PITX2 63,622 bp − 0.0153 0.0022 1.0 × 10−11 ↓ 
rs2106261 ZFHX3 cg06618356 16 73,097,364 ZFHX3 45,744 bp − 0.0096 0.0016 1.1 × 10−9 ↓ 
rs13216675 GJA1 cg05720511 6 123,043,994 PKIB 591,665 bp 0.0024 0.0005 1.6 × 10−6 ↓ 
Table 4.  Most significant CpG site associated with each AF GWAS locus. All loci were significantly 
associated methylation status (P < 8.3 × 10−6). +NCBI Genome Build 37. *SE: Standard error. $Indicate if AF 
risk allele was the same allele to increase methylation. “↑ ” Represents the AF risk allele would increase the 
methylation level, whereas “↓ ” represents the AF risk allele would decrease the methylation level.
Figure 3. Association of SNP rs6490029 (CUX2) with the methylation of cg10833066. The boxplot indicates 
the minimum, 25%, 50%, 75% and the maximum methylation level for each genotype. Outliers were marked as 
points. Samples with one or two “A” alleles at rs6490029 tended to have a higher methylation level. The number 
of samples with each genotype was marked as well.
www.nature.com/scientificreports/
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Materials and Methods
Study Samples. The Framingham Heart Study is a three-generation community-based cohort initiated in 
1948. The Framingham Offspring cohort was recruited in 1971, and consisted of 5124 participants who are the 
offspring and the spouses of offspring of the Original cohort42. The present study was focused on Offspring cohort 
participants who attended the eighth examination (2005–2008). All participants gave written informed consent 
and the study was approved by the Institutional Review Boards of National Human Genome Research Institute 
and Boston University Medical Center, and all experiments were performed in accordance with relevant guide-
lines and regulations.
AF Ascertainment. AF was ascertained from a combination of multiple sources. Each participant was asked 
about his/her cardiovascular history and a 12-lead electrocardiogram was obtained during clinic visits scheduled 
every 4–8 years. Additional information also was solicited during surveillance interviews biennially43,44, and from 
cardiovascular disease-related hospitalizations and clinician visits. At least two Framingham Heart Study cardi-
ologists reviewed all electrocardiograms available from study visits or in- and outpatient records to adjudicate 
incident AF.
DNA Methylation Quantification. The fasting peripheral whole blood was collected using Gentra 
Puregene Blood Kits (QIAGEN, Venlo, Netherlands) in a single examination (the eighth examination). The 
genomic DNA was then bisulfite-treated, amplified and hybridized to the Infinium HumanMethylation450 
BeadChip (Illumina, San Diego, CA) according to the manufacturer’s standard protocols45. The methylation assay 
was performed at two centers and normalized separately, and pooled together after adjusting for batch effects 
between two centers.
The methylation status was represented by the β value as a continuous variable between 0 and 1 representing 
the proportion of methylation at each CpG site. The raw data were normalized and corrected for the background 
noise by “DASEN” R package46. We excluded probes with detection P-values less than 0.01. The whole probe was 
removed if ≥ 1% of samples had missing values. A sample was removed if ≤ 95% probes had P-value < 0.01. We 
removed probes overlapping with known genetic polymorphisms from the 1000 Genomes Project Phase 147. Our 
analysis focused on autosomal chromosomes. A total of 443,252 CpG sites were included in the current study.
Gene Expression Profiling. Framingham gene expression profiling has been described in detail48–50. Briefly, 
total RNA was isolated from fasting peripheral whole blood collected during clinic visits. RNA was then amplified 
and reverse transcribed into cDNA, which was hybridized to the Human Exon 1.0st Array (Affymetrix, Santa Clara, 
CA) according to standardized protocols. We used Robust Multi-array Average51 method to normalize and sum-
marize the raw data. The gene annotations were obtained from Affymetrix NetAffx Analysis Center (version 31). 
Only the most reliable probe sets derived from RefSeq and GenBank records were used in this study, correspond-
ing to 17,873 distinct transcripts48–50.
Genetic Profiling. Genetic variation was profiled by Affymetrix 550 k Array (Affymetrix, Santa Clara, CA) as 
previously reported12. We excluded variants with call rates less than 97%, Hardy–Weinberg Equilibrium P -values 
less than 1.0 × 10−6, or minor allele frequencies less than 0.01. The remaining variants were imputed to HapMap 
r22 CEU panel by Mach (v 1.0.15)52.
Statistical Analyses. Our primary analysis tested the association between methylation and AF status. For 
prevalent AF analysis, we hypothesized that AF status could affect methylation level. We used linear mixed effects 
regression models to test the association between the methylation level of each CpG with prevalent AF. We speci-
fied the methylation level as the dependent measure and the AF status at the eighth examination as the exposure. 
For this analysis, both incident AF cases and participants with no history of AF served as the reference group. For 
the incident AF analysis, we hypothesized that DNA methylation could be associated with future risk of AF. We 
thus used Cox proportional hazards models to relate the methylation level at each CpG to incident AF (censored 
at the last follow-up time or death). Participants with prevalent AF at baseline were excluded from this analysis.
Both analyses were adjusted for age, sex, assay site, and pedigree structure in Framingham. The false dis-
covery rate (FDR)53 was used to correct for multiple testing, and statistical significance was claimed if the FDR 
was less than 0.05, corresponding to P < 1.4 × 10−7. For significant associations, we additionally adjusted for the 
proportion of six cell types imputed via a reference panel using the Houseman method54, including CD8+ T cells, 
CD4+ T cell, natural killer cells, B cells, monocytes and granulocytes, to account for cell count heterogeneity 
between study groups. In our secondary analysis, we tested the association of top CpG sites with AF adjusting for 
additional AF risk factors31, including smoking, height, weight, systolic blood pressure, diastolic blood pressure, 
prevalent diabetes mellitus, prevalent myocardial infarction, prevalent heart failure, and antihypertensive treat-
ment. In an additional exploratory analysis, we combined prevalent and incident AF cases to test the association 
of each CpG with AF.
We also developed a combined methylation score from CpG sites significantly associated with incident AF. 
The score for sample i is defined as β= ∑ = ⁎S Mi jn j ij1 , where n is the number of CpG sites significantly associated 
with incident AF, βj is the estimate of effect size for CpG site j, and Mij is the methylation level at CpG site j for 
sample i. Similarly, we developed a combined genetic score from 14 top AF loci that were published previ-
ously12–15. We then combined the genetic and methylation scores together with traditional AF risk factors, and 
investigated their association with incident AF using Cox proportional hazards models.
Association with Gene Expression. For each of the CpG sites associated with prevalent or incident AF, 
we examined the association of methylation with gene expression, stratified by cis-genes (defined as those within 
1 Mb of the CpG site), and trans-genes (defined as those more than 1 Mb away from the CpG site or in different 
www.nature.com/scientificreports/
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chromosomes). The association was tested by linear mixed effects regression models, whereas gene expression 
was treated as the dependent measure, and the methylation status was treated as the exposure, adjusted for age, 
sex, and family structure. We used Bonferroni correction to adjust for multiple testing, and the significance was 
defined as P < 0.05/N, where N is the number of tests.
Association with AF-related Genetic Loci. We examined the association between genetic variations 
associated with AF and DNA methylation. Our analysis was limited to the 14 SNPs that were previously reported 
to associate with AF susceptibility by GWAS12,13. The loci included rs10821415 (C9orf3), rs10824026 (SYNPO2L), 
rs1152591 (SYNE2), rs2106261 (ZFHX3), rs3807989 (CAV1), rs3903239 (PRRX1), rs6666258 (KCNN3), 
rs6817105 (PITX2), rs7164883 (HCN4), rs4642101 (CAND2), rs13216675 (GJA1), rs12415501 (NEURL), 
rs10507248 (TBX5), and rs6490029 (CUX2). Linear mixed effects regression models were used to test the asso-
ciation between each genetic variant and DNA methylation levels of CpGs within 1 Mb of AF SNPs. Methylation 
levels were treated as the dependent measures and genetic variants were treated as the exposures. The analysis 
was adjusted for age, sex, and family structure. We used Bonferroni correction to account for multiple testing, 
and the significance was claimed if the P value of the association was less than 0.05/N, where N was determined 
as the number of tests.
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